Pfizer's new drug HYMPAVZI has been approved by the US FDA for the treatment of hemophilia A and hemophilia B. On October 15th, Pfizer announced that HYMPAVZI (mataximab/mastacimab hncq) has recently been approved by the US Food and Drug Administration (FDA) for the regular treatment of hemophilia A (congenital factor VIII deficiency) or hemophilia B (congenital factor IX deficiency) patients over 12 years old without coagulation inhibitors, in order to reduce bleeding episodes. HYMPAVZI is Pfizer's second hemophilia treatment drug approved by the FDA this year.